• AAPL 173.18
  • TSLA 180.1
  • AMZN 184.72
  • MSFT 397.84
  • INTC 30.515
  • EURUSD 1.0745
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. ST /
  3. CANTA.ST

Cantargia AB (CANTA ST) stock market data APIs

kr3.316 0.07(2.2%) as of May 2, 2024

Cantargia AB Financial Data Overview

3.522
3.316
-
3.38
2.73
2.564-6.08
602 M
184 M
0
-0.4
1.574
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CANTA',
Type: 'Common Stock',
Name: 'Cantargia AB',
Exchange: 'ST',
CurrencyCode: 'SEK',
CurrencyName: 'Swedish krone',
CurrencySymbol: 'kr',
CountryName: 'Sweden',
CountryISO: 'SE',
OpenFigi: NULL,
ISIN: 'SE0006371126',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Cantargia AB Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -284 315 008
  • Earnings Per Share -1.65
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Cantargia AB Earnings via APIs

  • Latest Release 2024-02-22
  • EPS/Forecast NaN

Get Cantargia AB End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Cantargia AB latest news via APIs

Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023

LUND, Sweden, April 4, 2023 /PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead a...

Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer

LUND, Sweden, March 14, 2023 /PRNewswire/ -- Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported that two abstracts on its lead asset, the antibody nadunolimab (CAN04), have been selecte...
  • AACR
  • ABSTRACT NUMBER
  • CANCER
  • CANTARGIA AB
  • CHEMOTHERAPY
  • CLINICAL EFFICACY
  • LUNG METASTASES
  • METASTATIC CANCER
  • NASDAQ STOCKHOLM
  • PANCREATIC CANCER
  • PRECLINICAL RESULTS
  • TUMOR MICROENVIRONMENT
Do you have any questions?
support@eodhistoricaldata.com